Screener
Opus Genetics IRD EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Opus Genetics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034084
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Benefit (provision) for income taxes | — | — |
| Net loss | (65,535) | (8,194) |
| Other comprehensive loss, net of tax | — | — |
| Comprehensive loss | $(65,535) | $(8,194) |
| Net loss per share: | ||
| Basic and diluted | $(0.75) | $(0.24) |
| Number of shares used in per share calculations: | ||
| Basic and diluted | 86,891,352 | 33,884,920 |
Item 1. Financial Statements
FAQ
- What is Opus Genetics's EPS (diluted)?
- Opus Genetics (IRD) reported EPS (diluted) of -$0.75 in Q1 2026.
- How has Opus Genetics's EPS (diluted) changed year-over-year?
- Opus Genetics's EPS (diluted) decreased by 212.5% year-over-year, from -$0.24 to -$0.75.
- What is the long-term trend for Opus Genetics's EPS (diluted)?
- Over 4 years (2021 to 2025), Opus Genetics's EPS (diluted) has grown at a -34.7% compound annual growth rate (CAGR), from -$4.52 to -$0.82.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Opus Genetics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude